Leidi.com Lei Jianping September 16
Biopharmaceutical company Neumora Therapeutics (stock code: NMRA) was listed on Nasdaq in the United States yesterday.
Neumora's issuance price is $17, which is in the middle of the issuance range of $16 to $18. Neumora issued 14.71 million shares this time, raising a total of US$250 million.
Neumora's opening price was US$16.5, down 2.9% from the issue price; its closing price was US$16.25, down 4.41% from the issue price; based on the closing price, the company's market value was US$2.469 billion.
Annual loss of US$130 million
Neumora is a clinical-stage biopharmaceutical company developing therapeutics for a variety of brain disorders and neuropsychiatric and neurodegenerative diseases, matching the right patient populations with targeted therapies to reduce clinical trial risk and increase drug availability. Development success rate.
Neumora has two drugs in clinical trials, the most advanced of which is NMRA-140, a kappa opioid receptor antagonist used to treat major depression. Another drug in clinical trials is NMRA-511, which is being tested to treat agitation in Alzheimer's disease patients.
Neumora also plans to conduct a Phase 1 clinical trial of NMRA-266, a positive allosteric modulator of the M4 muscarinic receptor, for the treatment of schizophrenia.
As of now, Neumora has no revenue, with net losses of US$237 million and US$131 million in 2021 and 2022 respectively; operating losses in the first half of 2023 were US$81.23 million, and operating losses in the same period last year were US$74.55 million; net losses were US$74.17 million. US dollars, the net loss in the same period last year was US$73.41 million.
Cumulative funds raised exceeded US$600 million
Neumora has received multiple financings since its establishment. In October 2021, Neumora completed a US$500 million Series A financing. In October 2022, Neumora announced the completion of a US$112 million Series B financing to advance its treatment of neuropsychiatric diseases and neurodegeneration. Precision drug development for brain diseases such as brain diseases.
Before the IPO, Amgen held 24.4%, ARCH Venture Partners held 20.4%, Biomatics Capital Partners held 5.7%, SoftBank held 5.5%, and Paul L. Berns held 5.8%. , Kristina Burow holds 19%.
Paul L. Berns currently serves as the chairman of Neumora. In July 2023, Neumora had just undergone a management change and appointed Henry Gosebruch as the company's president, CEO and board member. Paul L. Berns resigned as CEO.
Gosebruch served as executive vice president and chief strategy officer of biopharmaceutical company AbbVie from December 2015 to February 2023. As a member of AbbVie's executive team, he created and led AbbVie's Corporate Strategy Office, which consisted of teams focused on corporate strategy.
After the IPO, Amgen holds 22% of the shares, ARCH Venture Partners holds 18.4%, Biomatics Capital Partners holds 5.2%, and SoftBank holds 5%;
Paul L. Berns holds 5.2% and Kristina Burow holds 17.2%.
The following is the Neumora roadshow PPT (edited by Leidi.com):
———————————————
Leidi was founded by media person Lei Jianping. If you reprint, please indicate the source.
